Gilead Sciences | GILD - Creditori Commerciali





Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Agios Pharmaceuticals USD 16.34M 2.6M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Amgen USD 2.86B 16.65B 2026-06
Biogen USD 403.9M 45.4M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Coherus Biosciences USD 13.17M 1.69M 2026-06
Eli Lilly USD 6.11B 1.08B 2026-06
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 7M 2026-06
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Incyte USD 1.39B 1.16B 2026-06
J&J USD 9.22B 1.24B 2026-06
Merck USD 3.83B 36M 2026-06
Moderna USD 167M 6M 2026-06
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.26B 64M 2026-06
Pfizer USD 4.58B 75M 2026-06
PTC Therapeutics USD 40.45M 14.96M 2026-06
Puma Biotechnology USD 6.39M 962K 2025-09
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Sangamo BioSciences USD 10.74M 7.46M 2025-06
Sanofi EUR 23.6B 888M 2026-06
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
United Therapeutics USD 497.8M 500K 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06